Weight-Loss drug may slow uterine tumors before surgery
NCT ID NCT07078838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether tirzepatide, a drug used for diabetes and weight loss, can slow or stop the growth of early-stage endometrial cancer or its precursor (EIN) in women with obesity. Forty participants will receive either tirzepatide or no additional treatment for 4 weeks before their planned hysterectomy. Researchers will compare tissue samples to see if tirzepatide reduces cell growth in the uterus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?